{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:42:16Z","timestamp":1792201336920,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>While headache is frequently encountered in patients with prolactinomas, data on its determinants and long-term outcome following upfront medical versus upfront surgical treatment are limited. We aimed to identify clinical and radiological determinants of prolactinoma-associated headache (PAH) and to evaluate long-term headache outcomes according to the primary treatment strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 145 prolactinoma patients treated at a tertiary center. Headache at presentation, endocrine parameters, tumor size, and cavernous sinus involvement were assessed. Independent determinants of PAH at diagnosis were identified using multivariable logistic regression. Long-term headache status and prolactin outcomes were evaluated according to upfront dopamine agonist (DA) therapy or transsphenoidal surgery (TSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At diagnosis, 42 of 145 patients (28.9%) presented with PAH. Compared with patients without PAH, those with PAH were older, more often male, and more likely to harbor macroadenomas and tumors with cavernous sinus involvement. In multivariable analysis, cavernous sinus involvement was the only independent factor associated with PAH (adjusted OR, 7.8; 95% CI, 1.2\u201348.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), whereas baseline prolactin levels were not independently associated. After a median follow-up of 80 months, headache prevalence declined from 28.9% to 2.8% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Durable headache improvement was observed after both DA therapy and transsphenoidal surgery, with no significant difference between treatment modalities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PAH is most strongly linked to tumor invasiveness rather than to prolactin levels alone. Durable headache relief is achieved with both upfront surgical and medical therapy, suggesting that effective tumor control, rather than the specific initial treatment approach, is the key determinant of headache improvement. These findings support careful patient counseling and underscore the importance of an individualized multidisciplinary approach in prolactinoma patients presenting with headache.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-026-01699-1","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T20:02:08Z","timestamp":1779566528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prolactinoma-associated headache: Clinical and radiological correlates and long-term outcomes"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1764-688X","authenticated-orcid":false,"given":"Lukas","family":"Andereggen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Stieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus M.","family":"Luedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atila","family":"Cihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Roethlisberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"2","key":"1699_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10194-008-0016-z","volume":"9","author":"D Bosco","year":"2008","unstructured":"Bosco D, Belfiore A, Fava A et al (2008) Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma. J Headache Pain 9(2):103\u2013107. https:\/\/doi.org\/10.1007\/s10194-008-0016-z","journal-title":"J Headache Pain"},{"issue":"16","key":"1699_CR2","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1177\/0333102412462639","volume":"32","author":"CJ Schankin","year":"2012","unstructured":"Schankin CJ, Reifferscheid AK, Krumbholz M et al (2012) Headache in patients with pituitary adenoma: clinical and paraclinical findings. Cephalalgia 32(16):1198\u20131207. https:\/\/doi.org\/10.1177\/0333102412462639","journal-title":"Cephalalgia"},{"issue":"3","key":"1699_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/neuros\/nyy087","volume":"84","author":"Y Hayashi","year":"2019","unstructured":"Hayashi Y, Sasagawa Y, Oishi M et al (2019) Contribution of Intrasellar Pressure Elevation to Headache Manifestation in Pituitary Adenoma Evaluated With Intraoperative Pressure Measurement. Neurosurgery 84(3):599\u2013606. https:\/\/doi.org\/10.1093\/neuros\/nyy087","journal-title":"Neurosurgery"},{"issue":"2","key":"1699_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11102-015-0696-8","volume":"19","author":"Y Hayashi","year":"2016","unstructured":"Hayashi Y, Kita D, Iwato M et al (2016) Significant improvement of intractable headache after transsphenoidal surgery in patients with pituitary adenomas; preoperative neuroradiological evaluation and intraoperative intrasellar pressure measurement. Pituitary 19(2):175\u2013182. https:\/\/doi.org\/10.1007\/s11102-015-0696-8","journal-title":"Pituitary"},{"issue":"4","key":"1699_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/0333102416648347","volume":"37","author":"B Yu","year":"2017","unstructured":"Yu B, Ji N, Ma Y, Yang B, Kang P, Luo F (2017) Clinical characteristics and risk factors for headache associated with non-functioning pituitary adenomas. Cephalalgia 37(4):348\u2013355. https:\/\/doi.org\/10.1177\/0333102416648347","journal-title":"Cephalalgia"},{"issue":"Pt 8","key":"1699_CR6","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/brain\/awh525","volume":"128","author":"MJ Levy","year":"2005","unstructured":"Levy MJ, Matharu MS, Meeran K, Powell M, Goadsby PJ (2005) The clinical characteristics of headache in patients with pituitary tumours. Brain 128(Pt 8):1921\u20131930. https:\/\/doi.org\/10.1093\/brain\/awh525","journal-title":"Brain"},{"issue":"7","key":"1699_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/0333102413515343","volume":"34","author":"MM Kallestrup","year":"2014","unstructured":"Kallestrup MM, Kasch H, Osterby T, Nielsen E, Jensen TS, Jorgensen JO (2014) Prolactinoma-associated headache and dopamine agonist treatment. Cephalalgia 34(7):493\u2013502. https:\/\/doi.org\/10.1177\/0333102413515343","journal-title":"Cephalalgia"},{"key":"1699_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jocn.2017.01.028","volume":"40","author":"L Andereggen","year":"2017","unstructured":"Andereggen L, Mono ML, Kellner-Weldon F, Christ E (2017) Cluster headache and macroprolactinoma: Case report of a rare, but potential important causality. J Clin Neurosci 40:62\u201364. https:\/\/doi.org\/10.1016\/j.jocn.2017.01.028","journal-title":"J Clin Neurosci"},{"issue":"2","key":"1699_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1468-1331.2003.00549.x","volume":"10","author":"MJ Levy","year":"2003","unstructured":"Levy MJ, Matharu MS, Goadsby PJ (2003) Prolactinomas, dopamine agonists and headache: two case reports. Eur J Neurol 10(2):169\u2013173. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12603293","journal-title":"Eur J Neurol"},{"key":"1699_CR10","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1699_CR11","doi-asserted-by":"publisher","unstructured":"Chen Y, Moutal A, Navratilova E et al (2020) The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females. Sci Transl Med 12(529). https:\/\/doi.org\/10.1126\/scitranslmed.aay7550","DOI":"10.1126\/scitranslmed.aay7550"},{"issue":"8","key":"1699_CR12","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/head.13612","volume":"59","author":"JDG Hiraldo","year":"2019","unstructured":"Hiraldo JDG, Sanchez Fernandez F, Fuerte Hortigon A, Viguera Romero FJ (2019) SUNCT Syndrome Secondary to Expanding Prolactinoma Responsive to Lamotrigine - A Case Report. Headache 59(8):1382\u20131384. https:\/\/doi.org\/10.1111\/head.13612","journal-title":"Headache"},{"issue":"7","key":"1699_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.nrl.2013.09.002","volume":"30","author":"L Pulido Fontes","year":"2015","unstructured":"Pulido Fontes L, Mayor Gomez S (2015) SUNCT (Short-lasting unilateral neuralgiform headache attack with conjunctival injection and tearing) associated with pituitary lesion. Neurologia 30(7):458\u2013459. https:\/\/doi.org\/10.1016\/j.nrl.2013.09.002","journal-title":"Neurologia"},{"issue":"6","key":"1699_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10194-009-0146-y","volume":"10","author":"J Zidverc-Trajkovic","year":"2009","unstructured":"Zidverc-Trajkovic J, Vujovic S, Sundic A, Radojicic A, Sternic N (2009) Bilateral SUNCT-like headache in a patient with prolactinoma responsive to lamotrigine. J Headache Pain 10(6):469\u2013472. https:\/\/doi.org\/10.1007\/s10194-009-0146-y","journal-title":"J Headache Pain"},{"key":"1699_CR15","doi-asserted-by":"publisher","first-page":"810219","DOI":"10.3389\/fendo.2022.810219","volume":"13","author":"M Huber","year":"2022","unstructured":"Huber M, Luedi MM, Schubert GA et al (2022) Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas. Front Endocrinol (Lausanne) 13:810219. https:\/\/doi.org\/10.3389\/fendo.2022.810219","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"1699_CR16","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s40618-021-01569-6","volume":"44","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH et al (2021) First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center. J Endocrinol Invest 44(12):2621\u20132633. https:\/\/doi.org\/10.1007\/s40618-021-01569-6","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1699_CR17","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1038\/s41598-021-84606-x","volume":"11","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH et al (2021) Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. Sci Rep 11(1):5122. https:\/\/doi.org\/10.1038\/s41598-021-84606-x","journal-title":"Sci Rep"},{"key":"1699_CR18","doi-asserted-by":"publisher","unstructured":"Mattogno PP, D\u2019Alessandris QG, Chiloiro S et al (2021) Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. Cancers (Basel) 13(13). https:\/\/doi.org\/10.3390\/cancers13133252","DOI":"10.3390\/cancers13133252"},{"issue":"4","key":"1699_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","volume":"65","author":"N Karavitaki","year":"2006","unstructured":"Karavitaki N, Thanabalasingham G, Shore HC et al (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 65(4):524\u2013529. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02627.x","journal-title":"Clin Endocrinol"},{"key":"1699_CR20","doi-asserted-by":"publisher","unstructured":"Andereggen L, Frey J, Christ E (2020) Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated. Endocr. https:\/\/doi.org\/10.1007\/s12020-020-02557-1","DOI":"10.1007\/s12020-020-02557-1"},{"issue":"2","key":"1699_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1699_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00234-011-0915-6","volume":"54","author":"L Andereggen","year":"2012","unstructured":"Andereggen L, Schroth G, Gralla J et al (2012) Selective inferior petrosal sinus sampling without venous outflow diversion in the detection of a pituitary adenoma in Cushing\u2019s syndrome. Neuroradiology 54(5):495\u2013503. https:\/\/doi.org\/10.1007\/s00234-011-0915-6","journal-title":"Neuroradiology"},{"issue":"3","key":"1699_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s11060-025-04958-6","volume":"172","author":"L Andereggen","year":"2025","unstructured":"Andereggen L, Christ E (2025) Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas. J Neurooncol 172(3):613\u2013623. https:\/\/doi.org\/10.1007\/s11060-025-04958-6","journal-title":"J Neurooncol"},{"key":"1699_CR24","doi-asserted-by":"publisher","first-page":"100258","DOI":"10.1016\/j.jcte.2021.100258","volume":"24","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH et al (2021) Impact of primary medical or surgical therapy on prolactinoma patients\u2019 BMI and metabolic profile over the long-term. J Clin Transl Endocrinol 24:100258. https:\/\/doi.org\/10.1016\/j.jcte.2021.100258","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"1699_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12020-016-1115-2","volume":"55","author":"L Andereggen","year":"2017","unstructured":"Andereggen L, Frey J, Andres RH et al (2017) 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 55(1):223\u2013230. https:\/\/doi.org\/10.1007\/s12020-016-1115-2","journal-title":"Endocrine"},{"issue":"11","key":"1699_CR26","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1007\/s00701-021-04830-2","volume":"163","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Mariani L, Beck J et al (2021) Lateral one-third gland resection in Cushing patients with failed adenoma identification leads to low remission rates: long-term observations from a small, single-center cohort. Acta Neurochir (Wien) 163(11):3161\u20133169. https:\/\/doi.org\/10.1007\/s00701-021-04830-2","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"1699_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neurad.2019.05.004","volume":"48","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Gralla J, Schroth G et al (2021) Influence of inferior petrosal sinus drainage symmetry on detection of adenomas in Cushing\u2019s syndrome. J Neuroradiol 48(1):10\u201315. https:\/\/doi.org\/10.1016\/j.neurad.2019.05.004","journal-title":"J Neuroradiol"},{"issue":"1","key":"1699_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s10194-023-01557-6","volume":"24","author":"AK Szewczyk","year":"2023","unstructured":"Szewczyk AK, Ulutas S, Akturk T et al (2023) Prolactin and oxytocin: potential targets for migraine treatment. J Headache Pain 24(1):31. https:\/\/doi.org\/10.1186\/s10194-023-01557-6","journal-title":"J Headache Pain"},{"issue":"2","key":"1699_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11102-025-01504-5","volume":"28","author":"CR Scaf","year":"2025","unstructured":"Scaf CR, Altoe A, Ventura N, Vincent M, Kasuki L, Gadelha MR (2025) Headache in pituitary adenomas: frequency, characteristics and outcome after treatment. Pituitary 28(2):31. https:\/\/doi.org\/10.1007\/s11102-025-01504-5","journal-title":"Pituitary"},{"issue":"10","key":"1699_CR30","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1046\/j.1526-4610.1998.3810782.x","volume":"38","author":"T Abe","year":"1998","unstructured":"Abe T, Matsumoto K, Kuwazawa J, Toyoda I, Sasaki K (1998) Headache associated with pituitary adenomas. Headache 38(10):782\u2013786. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11279904","journal-title":"Headache"},{"issue":"5","key":"1699_CR31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1526-4610.2005.05117_1.x","volume":"45","author":"K Negoro","year":"2005","unstructured":"Negoro K, Kawai M, Tada Y, Ogasawara J, Misumi S, Morimatsu M (2005) A case of postprandial cluster-like headache with prolactinoma: dramatic response to cabergoline. Headache 45(5):604\u2013606. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05117_1.x","journal-title":"Headache"},{"issue":"6","key":"1699_CR32","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1468-2982.2006.01101.x","volume":"26","author":"M Sarov","year":"2006","unstructured":"Sarov M, Valade D, Jublanc C, Ducros A (2006) Chronic paroxysmal hemicrania in a patient with a macroprolactinoma. Cephalalgia 26(6):738\u2013741. https:\/\/doi.org\/10.1111\/j.1468-2982.2006.01101.x","journal-title":"Cephalalgia"},{"issue":"11","key":"1699_CR33","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1136\/jnnp.74.11.1590","volume":"74","author":"MS Matharu","year":"2003","unstructured":"Matharu MS, Levy MJ, Merry RT, Goadsby PJ (2003) SUNCT syndrome secondary to prolactinoma. J Neurol Neurosurg Psychiatry 74(11):1590\u20131592. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14617728","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"1699_CR34","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1038\/s41433-024-03187-x","volume":"38","author":"MTM Wang","year":"2024","unstructured":"Wang MTM, Meyer JA, Danesh-Meyer HV (2024) Neuro-ophthalmic evaluation and management of pituitary disease. Eye (Lond) 38(12):2279\u20132288. https:\/\/doi.org\/10.1038\/s41433-024-03187-x","journal-title":"Eye (Lond)"},{"issue":"1","key":"1699_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10194-008-0084-0","volume":"10","author":"JA Gondim","year":"2009","unstructured":"Gondim JA, de Almeida JP, de Albuquerque LA, Schops M, Gomes E, Ferraz T (2009) Headache associated with pituitary tumors. J Headache Pain 10(1):15\u201320. https:\/\/doi.org\/10.1007\/s10194-008-0084-0","journal-title":"J Headache Pain"},{"issue":"7","key":"1699_CR36","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.neurol.2021.07.012","volume":"177","author":"LM Terrier","year":"2021","unstructured":"Terrier LM, Fontaine D (2021) Intracranial nociception. Rev Neurol (Paris) 177(7):765\u2013772. https:\/\/doi.org\/10.1016\/j.neurol.2021.07.012","journal-title":"Rev Neurol (Paris)"},{"issue":"8","key":"1699_CR37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0333102412472071","volume":"33","author":"S Akerman","year":"2013","unstructured":"Akerman S, Holland PR, Hoffmann J (2013) Pearls and pitfalls in experimental in vivo models of migraine: dural trigeminovascular nociception. Cephalalgia 33(8):577\u2013592. https:\/\/doi.org\/10.1177\/0333102412472071","journal-title":"Cephalalgia"},{"issue":"1","key":"1699_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11916-008-0014-5","volume":"12","author":"MJ Levy","year":"2008","unstructured":"Levy MJ, Matharu M, Goadsby PJ (2008) Chronic headache and pituitary tumors. Curr Pain Headache Rep 12(1):74\u201378. https:\/\/doi.org\/10.1007\/s11916-008-0014-5","journal-title":"Curr Pain Headache Rep"},{"issue":"8","key":"1699_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11916-018-0710-8","volume":"22","author":"H Suri","year":"2018","unstructured":"Suri H, Dougherty C (2018) Clinical Presentation and Management of Headache in Pituitary Tumors. Curr Pain Headache Rep 22(8):55. https:\/\/doi.org\/10.1007\/s11916-018-0710-8","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"1699_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11916-012-0267-x","volume":"16","author":"G Bussone","year":"2012","unstructured":"Bussone G, Usai S, Moschiano F (2012) How to investigate and treat: headache and hyperprolactinemia. Curr Pain Headache Rep 16(4):365\u2013370. https:\/\/doi.org\/10.1007\/s11916-012-0267-x","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"1699_CR41","doi-asserted-by":"publisher","first-page":"333102422113628","DOI":"10.1177\/03331024221136286","volume":"43","author":"MA Al-Karagholi","year":"2023","unstructured":"Al-Karagholi MA, Kalatharan V, Ghanizada H, Gram C, Dussor G, Ashina M (2023) Prolactin in headache and migraine: A systematic review of clinical studies. Cephalalgia 43(2):3331024221136286. https:\/\/doi.org\/10.1177\/03331024221136286","journal-title":"Cephalalgia"},{"issue":"8","key":"1699_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.tins.2020.06.003","volume":"43","author":"Y Chen","year":"2020","unstructured":"Chen Y, Navratilova E, Dodick DW, Porreca F (2020) An Emerging Role for Prolactin in Female-Selective Pain. Trends Neurosci 43(8):635\u2013648. https:\/\/doi.org\/10.1016\/j.tins.2020.06.003","journal-title":"Trends Neurosci"},{"key":"1699_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.isci.2019.09.039","volume":"20","author":"M Patil","year":"2019","unstructured":"Patil M, Belugin S, Mecklenburg J et al (2019) Prolactin Regulates Pain Responses via a Female-Selective Nociceptor-Specific Mechanism. iScience 20:449\u2013465. https:\/\/doi.org\/10.1016\/j.isci.2019.09.039","journal-title":"iScience"},{"issue":"12","key":"1699_CR44","doi-asserted-by":"publisher","first-page":"e70098","DOI":"10.1111\/jne.70098","volume":"37","author":"AJ Hjelholt","year":"2025","unstructured":"Hjelholt AJ, Tei RMH, Diener HC, Jorgensen JOL (2025) Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets. J Neuroendocrinol 37(12):e70098. https:\/\/doi.org\/10.1111\/jne.70098","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"1699_CR45","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/head.14927","volume":"65","author":"G Giuliani","year":"2025","unstructured":"Giuliani G, Costa D, Pellicano C et al (2025) Headache characteristics in acromegaly: Only a secondary disorder? Headache 65(5):826\u2013834. https:\/\/doi.org\/10.1111\/head.14927","journal-title":"Headache"},{"issue":"9","key":"1699_CR46","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","volume":"108","author":"RS Auriemma","year":"2023","unstructured":"Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R (2023) Approach to the Patient With Prolactinoma. J Clin Endocrinol Metab 108(9):2400\u20132423. https:\/\/doi.org\/10.1210\/clinem\/dgad174","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1699_CR47","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol 19(12):722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1699_CR48","doi-asserted-by":"publisher","first-page":"9598","DOI":"10.1038\/s41598-025-90250-6","volume":"15","author":"L Andereggen","year":"2025","unstructured":"Andereggen L, Christ E, Stieger A, Luedi MM, Huber M (2025) Gender differences in prolactin thresholds and their association with lactotroph adenoma invasiveness for potential treatment considerations. Sci Rep 15(1):9598. https:\/\/doi.org\/10.1038\/s41598-025-90250-6","journal-title":"Sci Rep"},{"key":"1699_CR49","doi-asserted-by":"publisher","first-page":"967407","DOI":"10.3389\/fsurg.2023.967407","volume":"10","author":"L Andereggen","year":"2023","unstructured":"Andereggen L, Tortora A, Schubert GA et al (2023) Prolactinomas in adolescent and elderly patients-A comparative long-term analysis. Front Surg 10:967407. https:\/\/doi.org\/10.3389\/fsurg.2023.967407","journal-title":"Front Surg"},{"key":"1699_CR50","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.wneu.2016.10.059","volume":"97","author":"L Andereggen","year":"2017","unstructured":"Andereggen L, Frey J, Andres RH et al (2017) Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health. World Neurosurg 97:595\u2013602. https:\/\/doi.org\/10.1016\/j.wneu.2016.10.059","journal-title":"World Neurosurg"},{"key":"1699_CR51","doi-asserted-by":"publisher","first-page":"1363431","DOI":"10.3389\/fsurg.2024.1363431","volume":"11","author":"M Huber","year":"2024","unstructured":"Huber M, Luedi MM, Schubert GA et al (2024) Gender-specific prolactin thresholds to determine prolactinoma size: a novel Bayesian approach and its clinical utility. Front Surg 11:1363431. https:\/\/doi.org\/10.3389\/fsurg.2024.1363431","journal-title":"Front Surg"},{"key":"1699_CR52","doi-asserted-by":"publisher","first-page":"695498","DOI":"10.3389\/fendo.2021.695498","volume":"12","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Christ E, Commentary (2021) Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery. Front Endocrinol (Lausanne) 12:695498. https:\/\/doi.org\/10.3389\/fendo.2021.695498","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1699_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","volume":"23","author":"J Honegger","year":"2020","unstructured":"Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S (2020) Surgery for prolactinomas: a better choice? Pituitary 23(1):45\u201351. https:\/\/doi.org\/10.1007\/s11102-019-01016-z","journal-title":"Pituitary"},{"key":"1699_CR54","doi-asserted-by":"publisher","unstructured":"Ordonez-Cure S, Uparela-Reyes MJ, Cardona-Collazos S, Fernandez-Osorio AD, Orozco J (2025) Prolactinomas and Knosp grade: when is surgery the appropriate choice? A systematic review and meta-analysis. J Neurosurg 1\u201310. https:\/\/doi.org\/10.3171\/2025.5.JNS243092","DOI":"10.3171\/2025.5.JNS243092"},{"issue":"4","key":"1699_CR55","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Cappabianca P et al (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89(4):1704\u20131711. https:\/\/doi.org\/10.1210\/jc.2003-030979","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1699_CR56","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485\u2013534. https:\/\/doi.org\/10.1210\/er.2005-9998","journal-title":"Endocr Rev"},{"issue":"1","key":"1699_CR57","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00701-024-06213-9","volume":"166","author":"L Andereggen","year":"2024","unstructured":"Andereggen L, Tortora A, Schubert GA et al (2024) Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma. Acta Neurochir (Wien) 166(1):314. https:\/\/doi.org\/10.1007\/s00701-024-06213-9","journal-title":"Acta Neurochir (Wien)"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01699-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01699-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01699-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:15:10Z","timestamp":1792199710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01699-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1699"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01699-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study used existing clinical and registry data only. No direct patient contact was involved, and no additional patient consent process was required for the study. Ethical approval for the analysis of institutional data was granted by the Human Research Ethics Committee of Bern (Kantonale Ethikkommission Bern, KEK Bern, Bern, Switzerland) under reference numbers KEK 10-10-2006 and KEK 8-11-2006. All procedures were performed in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","label":"Compliance with ethical guidelines","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"94"}}